Seroprevalence of hepatitis E virus (HEV) in a general adult population 
in Northern Norway: the Tromsø study by Olsøy, Irene Beate et al.
1 
Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the Tromsø 
study 
Irene Beate Olsøy1, Stian Henriksen1, 2, Fabian H. Weissbach3, Marthe Larsen4 Karoline Borgen2, Florence 
Abravanel5,6,7, Nassim Kamar5,7,8,, Eyvind J. Paulssen9,10, Hans H. Hirsch3,11,12 Christine Hanssen Rinaldo1,2,# 
1 Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway  
2 Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway 
3 Transplantation & Clinical Virology, Department of Biomedicine (Haus Petersplatz), University of Basel, 
Basel, Switzerland  
4 Department of Clinical Research, University Hospital of North Norway, Tromsø, Norway 
5 Centre De Physiopathologie De Toulouse Purpan, Inserm, U1043; Toulouse, France. 
6 Laboratoire de virologie, Centre national de référence du virus de l'hépatite E, Hôpital Purpan, CHU Toulouse 
Toulouse, France 
7 Université Paul Sabatier, Toulouse, France 
8 Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France 
9 Gastroenterology and Nutrition Research Group, Department of Clinical Medicine, UiT The Arctic University 
of Norway, Tromsø, Norway. 
10 Department of Internal Medicine, Section of Gastroenterology, University Hospital of North Norway, Tromsø, 
Norway 
11 Division Infection Diagnostics, Department of Biomedicine (Haus Petersplatz), University of Basel, Basel, 
Switzerland. 
12 Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland 
#Corresponding author:  
Christine Hanssen Rinaldo 
e-mail: christine.rinaldo@unn.no
Telephone number: +47 77 75 58 64 
ORCID: 0000-0002-6970-6728 
Manuscript Click here to
access/download;Manuscript;renamed_225bb.docx
Click here to view linked References
2 
Abstract 
Hepatitis E virus (HEV) is a major cause of acute viral hepatitis in many parts of the world but only a few cases 
have been diagnosed in Norway. To investigate the HEV exposure rate in a presumed low-risk area, we have 
conducted a population-based study of anti-HEV IgG seroprevalence in Northern Norway. A total of 1800 serum 
samples from 900 women and 900 men, age 40-79 years, were randomly selected from the 21083 participants in 
the 7th Tromsø Study, representing the 32591 inhabitants of the Tromsø municipality that were ≥40 years. All 
samples were analyzed by ELISA-1 (recomWell HEV IgG). Samples testing positive or borderline, as well as a 
1.5-fold excess of negative samples, were retested by ELISA-2 (DiaPro HEV IgG). If still borderline or a result 
discordant from ELISA-1, the sample was retested by ELISA-3 (Wantai HEV IgG) and strip-immunoassay 
(recomLine HEV IgG). Anti-HEV IgG was detected in 205 individuals (11.4%), yielding an estimated 
seroprevalence of 10.4% in the age-matched population of Tromsø. Using logistic regression analysis followed by 
multivariable backward elimination analysis, increasing age (OR 1.036; p<0.001) and higher education (OR 2.167; 
p<0.001) were found as potential risk factors, whereas travel abroad or eating of red meat was not. Our results 
indicate that HEV-infection is common in Northern Norway and suggest that HEV testing should be included in 
the evaluation of elevated liver enzymes.  
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Hepatitis E virus (HEV) infection is a major cause of acute viral hepatitis worldwide (1-3). HEV infection may 
cause acute liver failure in pregnant women and patients with preexisting liver disease, as well as chronic hepatitis 
with rapid progression of liver fibrosis in immunocompromised patients (4). In addition, neurological 
manifestations, kidney injury, pancreatitis and hematological disorders have been reported (5, 6). However, most 
people infected by HEV are believed to have an asymptomatic self-limiting course (7).  
HEV is a non-enveloped, single-stranded, positive sense RNA virus that belongs to the Hepeviridae family. Based 
on phylogenetic analysis of many HEV isolates, seven genotypes (GT) have been found in mammals, all belonging 
to a single serotype (8). Five of the genotypes have been shown to infect humans in different geographical locations 
and by different modes of transmission. HEV GT1 and GT2 are highly endemic in Asia, Africa, the Middle East 
and Mexico where they cause large outbreaks due to fecal-oral transmission from contaminated drinking water. 
HEV GT7 has been found in camels in the Middle East and was found to infect one person regularly consuming 
camel milk and meat (9). In Europe, HEV GT3 is the most prevalent genotype, followed by GT4. Both genotypes 
can infect animals such as domestic pigs, wild boar, and deer, and for GT3 also rabbits, and are sporadically 
transmitted to humans through direct contact with infected animals or indirectly by consumption of undercooked 
HEV-containing animal products (8). Transmission may also occur through consumption of shellfish, and 
contaminated berries and vegetables (10-12). HEV can be transmitted through blood and blood products, through 
solid organ transplantation, and by vertical transmission from mother to fetus. Recently, the United Kingdom, 
Ireland, France, Japan and the Netherlands have implemented universal, targeted or partial HEV screening of 
donor blood to avoid HEV transmission by blood transfusion (3). 
Anti-HEV IgG seroprevalence and incidence of hepatitis E varies both between and within countries. In Europe, 
seroprevalence rates ranging from 0.035% to 60.9% have been reported (13, 14) with “hot-spots” in southwest 
France, the Netherlands, Scotland, western Germany, Czech Republic, central Italy and western/central Poland 
(3). There is limited knowledge about HEV in Norway. One study, investigating 1200 blood donors, 79 swine 
farm workers and 153 pig herds (15) found anti-HEV IgG antibodies in 14% of the blood donors, 30% of the swine 
farm workers and in 90% of the investigated pig herds. There is also one case report on acute HEV-infection in a 
20-year young Norwegian man with no recent travel history (16).
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The aim of this study was to determine the exposure to HEV in a presumably low-risk adult population in Northern 
Norway. Since commercially available serological immunoassays have been reported to vary in sensitivity and 
specificity (17-19), a testing, retesting and confirmation strategy was defined using four different immunoassays 
in accredited collaborating laboratories.  
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Materials and Methods 
 
Study population and samples  
The 7th Tromsø Study (Tromsø 7) is the latest of a series of population-based surveys since 1974 in the municipality 
of Tromsø in Northern Norway (20) and was carried out in 2015-16. Residents of age 40 and above were all 
invited, and 21 083 women and men (64.7% of eligible subjects) participated (Table 1). The study was performed 
in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. 
Ethical permission was obtained from the Regional Committee for Medical Research Ethics – South East Norway. 
Informed consent was obtained from all individual participants included in the study. To ensure a representative 
study population, we included serum samples from 1800 randomly selected participants, age 40-79 years, 
consisting of 900 women and 900 men in four age strata of equal size (Table 2). All samples were kept frozen at 
-20°C until tested for anti-HEV IgG in Tromsø. The samples were aliquoted in two additional tubes for retesting 
in collaborating labs. 
 
Immunoassays for anti-HEV IgG detection 
For detection of anti-HEV IgG, four commercially available HEV immunoassays were used in three different labs 
(Table 3), all according to the manufacturer´s instructions. RecomWell HEV IgG enzyme-linked immunosorbent 
assay (ELISA) was selected for the first test of all 1800 sera and this test is from now on denoted ELISA-1. For 
retesting of all ELISA-1 IgG positive or borderline samples and 1.5-times the number of ELISA-1 non-reactive 
samples, DiaPro HEV IgG ELISA (ELISA-2) was used. All samples with borderline result or discordant result 
between ELISA-1 and ELISA-2 were retested by Wantai HEV IgG ELISA (ELISA-3) and RecomLine IgG (strip-
immunoassay).  For ELISA-1 the antibody activity in units per mL (U/mL) was calculated by dividing the 
extinction value of the sample by the mean of the extinction values of the cutoff and multiplying this by 20, while 
for ELISA-2 and ELISA-3 antibody activity was calculated by dividing the extinction value of the sample by the 
mean of the extinction values of the cutoff (S/Co). 
 
The strip-immunoassay consists of nitrocellulose membrane test-strips with seven purified recombinant HEV GT1 
and GT3 antigens from open reading frame 2 (ORF2), encoding the viral capsid protein, and open reading frame 
3 (OFR3), encoding a multifunctional protein (O2N: N-terminal part of ORF2 protein GT1 and GT3; O2M: middle 
part of ORF2 GT1 and GT3; O2C: C-terminal part of ORF2 protein GT1 and GT3 and O3: the full length ORF3 
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GT1). Antibodies to the different antigens were present if the respective band was of an intensity equal to or 
stronger than the intensity of the reference (cutoff) band. As defined by the manufacturer, the different bands gave 




To measure inter-rater agreement between different assays, Weighted Kappa statistics was used 
(https://www.graphpad.com/quickcalcs/kappa1.cfm). Due to the binary outcome (anti-HEV IgG positive or anti-
HEV IgG negative), logistic regression (IBM SPSS version 24) was used to look at associations between a positive 
anti-HEV IgG result and potential risk factors from the self-reported questionnaires in Tromsø 7. Age, body-mass 
index (BMI), traveling for more than one week outside the Nordic countries during the last 12 months, the number 
of times of eating moose meat per year, and the number of times of eating reindeer meat per year were used as 
continuous variables. The level of education, the household income, smoking habits, diabetes, gender, alcohol 
habits and eating of red meat were entered as categorical variables. Recoding of some original groupings were 
necessary due to small groups. Age-adjusted logistic regression was performed for each of the variables and 
variables with a p-value <0.25 were selected as candidates for further multivariable analysis. All candidate 
variables were included in the multivariable model and the variable with the least significant p-value was omitted. 
This backward elimination process with a re-fitted model at each step was repeated until all variables were 
statistically significant. The inclusion in the final model was based on a significance level of 0.05. The predicated 
probability of a positive test was calculated by transforming the regression coefficients from the log odds scale 




Selection of representative serum samples for the anti-HEV IgG seroprevalence study 
At the time of planning and initiation of this study, there was no data available on anti-HEV IgG seroprevalence 
in Norway. In order to select a representative adult population in Tromsø, we assumed a minimum of 2% 
seroprevalence and included 1800 individuals (Table 1). Since 96.4% of the study participants of Tromsø 7 were 
40 to 79 years old, we randomly selected 225 women and 225 men in each of the following age groups: 40 - 49 
years, 50 - 59 years, 60 - 69 years and 70 - 79 years (Table 2). Comparing the demographics of the HEV study 
population and the entire Tromsø 7 revealed no significant differences in age, except for the age group 70 - 79 
years that was overrepresented in our study. 
    
Anti-HEV IgG activity in 1800 serum samples using ELISA-1 
All 1800 serum samples were first tested by ELISA-1. The result showed 198 (11%) anti-HEV IgG positive 
samples (>24.0 U/mL), 1589 (88.3%) anti-HEV IgG negative samples (<20.0 U/mL), and 13 (0.7%) undetermined 
samples due to borderline results (20 - 24 U/mL) (Fig. 1a). The frequency histogram showed that the IgG positive 
samples ranged from 24.1 to 78.7 U/mL, giving one peak around 28 - 32 U/mL and one smaller peak around 64 - 
68 U/mL (Fig. 1b). No correlation between anti-HEV IgG activity and age or gender was found (data not shown). 
Looking at the negative samples, 1557 samples (98%) had an IgG level below 8.0 U/mL Thus, ELISA-1 indicated 
an anti-HEV IgG seroprevalence of 11.0% in the study population.  
 
Comparison of anti-HEV IgG activities of 513 samples using ELISA-1 and ELISA-2 
The serum samples having an ELISA-1 positive results (n=198) or borderline (n=13) results were retested by 
ELISA-2. In addition, 302 ELISA-2 negative samples were retested, which included all 13 samples with a result 
between 10 and 19.9 U/mL. Of totally 513 retested serum samples, ELISA-2 yielded 178 positive samples (S/Co 
> 1.1), 319 negative samples (S/Co < 0.9), and 16 samples with borderline result (S/Co 0.9 - 1.1). Thus, the results 
of ELISA-1 and ELISA-2 were concordant for 476 samples (92.8%), but discordant for 37 samples (7.2%) 
(Supplementary Table 1). The concordant results consisted of 174 anti-HEV IgG positive (36.6%), 5 borderline 
(1.0%), and 297 negative (62.4%) samples, while the discordant results consisted of 18 fully discordant  (e.g. 
positive vs. negative), and 19 partial discordant samples (i.e. being positive or negative in one, and borderline in 
the other test). Based on these numbers, a weighted Kappa of 0.886 was calculated indicating a very good 
qualitative agreement between ELISA-1 and ELISA-2.  
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To compare the quantitative results of ELISA-1 and ELISA-2, the results of ELISA-1 were plotted on the X-axis 
(U/mL) and the results of ELISA-2 (S/Co) were plotted on the Y-axis (Fig. 2a). For all samples with concordant 
positive (red dots), negative (green dots) and borderline result (yellow dots), the anti-HEV IgG activity in ELISA-
1 appeared to correlate with the activity measured by ELISA-2. Moreover, all 24 fully or partly discordant samples 
that were positive in ELISA-1, showed relatively low IgG levels (mean values of 28.6 U/mL) compared to the 
mean value of all 198 ELISA-1 positive samples (47.3 U/mL).  In contrast, two of the three fully discordant 
samples that were only positive in ELISA-2, had high IgG levels (mean value of 3.84 S/Co) compared to the mean 
value of all 178 ELISA-2 positive samples (3.62 S/Co). Thus, with the exception of these two samples, a good 
agreement between the quantitative results of ELISA-1 and ELISA-2 was found. Restricting the seroprevalence 
rate to only the concordant ELISA-1/ELISA-2 positive samples (n=174), the minimum estimate of anti-HEV IgG-
positivity was 9.7%. 
 
Testing of indeterminate and discordant sera by ELISA-3 and strip-immunoassay 
To better define the HEV IgG status of the five samples with concordant borderline results and the 37 discordant 
samples, retesting with ELISA-3 and the strip-immunoassay was done. Samples were scored positive if positive 
in at least two of the four assays used. As summarized in Fig. 2b, the five samples with a concordant borderline 
result were positive in both ELISA-3 and the strip-immunoassay and hence defined as positive. Of the 18 fully 
discordant sera, the 15 ELISA-1 positive sera were all defined as positive since they were positive by the strip-
immunoassay (14 were positive by ELISA-3), while the three ELISA-2 positive sera were all defined as negative 
since they were negative by both ELISA-3 and the strip-immunoassay.  
 
The 10 partial discordant samples that were positive by ELISA-1 or ELISA-2, were all found to be positive as they 
were positive by ELISA-3 (eight were positive by strip-immunoassay). In addition, one sera borderline by ELISA-
1 and negative by ELISA-2 was found to be positive by both ELISA-3 and strip-immunoassay (Fig. 2b). Based 
on the confirmatory testing by ELISA-3 and strip-immunoassay, 31 additional individuals were judged as being 
anti-HEV IgG positive. This increased the number of HEV-exposed individuals to 205 (11.4%) consisting of 98 
(10.9%) women and 107 (11.9%) men. Compared to the first testing by ELISA-1, the seroprevalence in the study 
population increased by 0.4% from 11.0% to 11.4%. Of note, 27 of 29 samples (93%) testing positive by strip-
immunoassay, had antibodies only against O2C. All O2C positive samples had a strong GT3 band and a weak 
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GT1 band, with the exception of one sample giving equally strong GT1 and GT3 bands. Moreover, two of the five 
samples with a slightly weaker O2C band than the cutoff, were found to be positive due to positive ELISA results.  
 
Anti-HEV IgG seroprevalence in the age-matched population of Tromsø 
In order to estimate the anti-HEV IgG seroprevalence in the age-matched population of Tromsø, the 
seroprevalence was calculated considering the number of residents in each age group (Table 1). This gave an 
average seroprevalence of 10.4%.  
 
Potential risk factors for a positive anti-HEV IgG activity  
Twelve potential risk factors for anti-HEV IgG were identified in the survey questionnaire of Tromsø 7 and 
answers registered (Supplementary Table 2). An age-adjusted logistic regression analysis was performed for 
each of these variables (Table 4).  Six factors were found to have a p-value below 0.25 and were included in a 
backward multivariable regression analysis. The only factors remaining in the final adjusted model were increasing 
age and education for ≥4 years in college or university (Table 5). The predicted probability for a positive anti-
HEV IgG test translated into a smooth, almost linear increase with age (Fig. 3a). Thus, the odds of having a 
positive anti-HEV IgG test, increases by a factor of 1.036 for each additional year above 40 years of age (95% CI: 
1.021-1.051, p<0.001). In addition, the odds of a positive anti-HEV IgG test was 2.167 times higher in the highest 
education category compared to the lowest education category (95% CI: 1.415-3.319, p<0.001). The predicted 
probability for a positive anti-HEV IgG test shows a steeper increase with increasing age for those with more than 
4 years of college or university compared to those with only primary school (Fig. 3b). In conclusion, only increased 




In this population-based study, the anti-HEV IgG seroprevalence of adults in a presumably low-risk geographic 
area in Northern Norway was examined. By analyzing 1800 serum samples from participants age 40-79 years in 
the Tromsø 7 study, the anti-HEV IgG seroprevalence was determined to be 10.4% in the age-matched population 
of Tromsø municipality. No significant difference in seroprevalence was seen between woman and men. When 
analyzing 12 potential risk factors obtained from the self-reported questionnaires (return rate >90%) using logistic 
regression analysis followed by multivariable backward elimination analysis, only increasing age (OR of 1.036 
per year; 95% CI: 1.021-1.051, p<0.001) and higher education (OR 2.167; 95% CI: 1.415-3.319, p<0.001) were 
found to be significantly associated with anti-HEV IgG.  
The anti-HEV IgG seroprevalence of 10.4% is surprisingly high but in the lower range of the ones previously 
reported from other European countries. A meta-analysis including 73 European studies conducted between 2003 
and 2015 concluded that HEV seroprevalence varied between and within countries, depended on the assay used, 
was higher in individuals exposed to pigs and/or wild animals and increased with age (21). In agreement with the 
geographic variation described within countries, we found a lower seroprevalence than the 14.0% reported in the 
study of 1200 Norwegian blood donors mainly from South Norway (15). This difference can not be explained by 
age, as the median age of the blood donors was 45 years (range from 18 to 83 years, data available from only 999 
blood donors), compared to the median age of 59.3 years for the participants in our study. The seroprevalence for 
blood donors above 50 years was about twice as high as what we found for the similar age groups in our study 
(51-60 years: 22% and 61-83 years: 28% versus 50-59 years: 10.4%; 60-69 years: 13.3% and 70-79 years:15.1%) 
arguing for a higher exposure rate with increasing age in South Norway. Although we cannot exclude that the 
difference is at least in part due to the use of different assays, we suspect that many of the blood donors were from 
areas where industrial agriculture and pig farming is more common than in Northern Norway.  
 
Given the reported difference in sensitivity of different serology assays and the absence of gold standards defining 
false-positive results (specificity), we developed a careful testing, retesting and confirmation strategy with up to 
four different immunoassays, which were performed in different accredited laboratories. Scoring samples positive 
only if at least two of the four assays were reactive, 205 participants were anti-HEV-positive yielding an anti-HEV 
seroprevalence of 11.4% in the examined population. Using a stricter definition scoring fully discordant samples 
positive only if both confirmatory assays were reactive, 196 participants were anti-HEV-positive yielding a 
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seroprevalence of 10.9%, which is not significantly different than 11.4% (p=0.63). Although the strip-
immunoassay contains seven recombinant HEV antigens from four different epitopes, according to the 
manufacturer it is sufficient to have a single O2C band (GT1 or GT3) above the reference intensity for the test to 
be positive. As detailed in the results, all 29 positive samples had antibodies against O2C, and only two of these 
samples had antibodies against other antigens, thereby questioning the added value of these antigens. Others 
reported similar findings when using the previous version of the assay (18). Moreover, it can be questioned whether 
the manufacturer’s scoring system is too strict since two samples with an O2C band slightly weaker than the 
reference band get the score zero but are positive by ELISA. Unfortunately, the strip-immunoassay using antigens 
from GT1 and GT3 can not be used for genotyping, probably since both genotypes belong to the same serotype. 
 
Although symptomatic acute HEV-infection is reported to mainly affect males above 50 years (22) we found no 
association between anti-HEV IgG positivity and gender. Similar results have been found in other studies (23, 24), 
indicating that men are not more frequently infected than women but may be more likely to become symptomatic. 
Whether or not this is due to gender differences or hepatotoxic insults remains to be examined. We did not find an 
association between seropositivity and diabetes, BMI, smoking, alcohol consumption, travelling outside the 
Nordic countries for more than one week the last 12 months, household income or eating of meat. Since a high 
frequency of HEV with a high genetic similarity to GT3 and GT4 has been reported in moose in Sweden (25), 
another Scandinavian country, and since people in the arctic region eat moose- and reindeer meat, we looked for 
an association with yearly intake of these. However, no association with anti-HEV seropositivity was found. Since 
moose meat is not readily available in markets, intake of moose meat can be a surrogate marker of hunting big 
game. In other European regions, hunters have an increased risk of HEV infection (26-28). This does not seem to 
be the case in Tromsø municipality, probably since wild boar and deer are not part of the fauna. 
 
The two independent risk factors found in our population-based study were increasing age and having more than 
four years of college or university education. The odds of a positive anti-HEV IgG test increased by 3.6% for each 
additional year above 40. An increased seroprevalence with increasing age has also been found in several other 
studies (24, 29, 30). Of note, the levels of the anti-HEV IgG titers (Fig. 1b) did not decrease with increasing age 
as has been reported for some viruses such as BK polyomavirus (31, 32). This suggests that the cumulative increase 
in HEV IgG seropositivity may be due to infection/re-infection throughout life, even in elderly with a more 
senescent immune response. However, the detailed long-term dynamic of naturally acquired anti-HEV IgG is 
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largely unknown (reviewed in (33)), and should be investigated using consecutive samples from patients with 
acute HEV-infection. The finding that people with higher education were more frequently anti-HEV IgG positive 
than people with less education is in contradiction to a study from the Netherlands (34). One explanation could be 
that many people with higher education living in Tromsø may originate from other areas inside or outside Norway 
where HEV is more prevalent and have moved to Tromsø due to studies or work at the local university or university 
hospital. Alternatively, this may reflect yet undefined food or travel habits. Unfortunately the Tromsø 7 study did 
not include participants below 40 years of age, which would have enabled a more comprehensive study of the 
population of Tromsø. 
 
Autochthonous cases of HEV in Western European countries are mainly caused by HEV GT3 and some small 
outbreaks have been directly linked to consumption of undercooked or raw pork products or shellfish (35, 36). GT3 
was probably also the cause of infection in most of our seropositive participants, but this would be difficult to 
prove due to the normally very short viraemic phase and the lack of a genotype-specific serology test. Although 
the majority of the participants (72.5%) did report eating meat weekly, this was not found to be a risk factor for 
anti-HEV IgG seropositivity. This as opposed to a study from the Netherlands reporting significantly higher 
seroprevalence among blood donors consuming meat on daily basis compared to vegetarian donors (37). Although 
extensive, the Tromsø 7 questionnaire did not distinguish between eating beef, mutton or pork and did not identify 
exclusive vegetarians, which may have affected the outcome. In 2016 the red meat consumption per Norwegian 
inhabitant was calculated to be 51 kg per year and about half of this was pork meat (38). Although the consumption 
of red meat has increased by about 15% the last 30 years, it is still lower than reported from Sweden, Finland, 
Denmark, France, Finland, England and USA. In the municipality of Tromsø, there are no pig farms, wild boars, 
wild rabbits or deer. Together, this supports that Tromsø is a low-risk geographic area.  
 
What could be the source explaining a 10% HEV-exposure rate among adult inhabitants of Tromsø? Some 
commonly suggested risk factors missing in the questionnaire were consumption of shellfish, received blood 
transfusion and transplantation. In addition, the consumption of agricultural products such as unpeeled fruits, 
berries, raw vegetables such as lettuce, should have been investigated. These food items have been suggested to 
be a source of HEV (10, 12, 39) and are frequently imported to Northern Norway. Recently, an anti-HEV IgG 
seroprevalence of 56.6% and 32.2% was found in dogs and cats in Germany (40). Since no viral RNA could be 
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isolated, the genotype is still not known. However, if HEV from dogs and cats can infect humans, this could very 
well be an important source of HEV infection in Tromsø. 
  
In conclusion, this carefully performed population-based study indicates an anti-HEV IgG seroprevalence of 
10.4% among adults in Tromsø municipality. The seroprevalence was similar for women and men and increased 
with increasing age. Despite attempts to better define the risk for HEV infection, the primary source of HEV 
infection if existing, is undefined. Our data justify to recommend HEV testing in all patients with elevated liver 
enzymes, which is not the present routine in most Norwegian hospitals. 
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Fig. 1. ELISA-1 anti-HEV IgG reactivity in 1800 participants of the population-based study Tromsø 7.  
a. The results are presented as total number of samples with negative (white), borderline (grey) or positive 
(black) anti-HEV IgG detection.  
b. A frequency histogram of the results divided in 4 U/mL intervals. The results are presented as negative (white), 
borderline (grey) or positive (black) anti-HEV IgG detection.  
 
Fig. 2. Anti-HEV IgG reactivity in 513 selected samples from the population-based study Tromsø 7. 
a. The qualitative and quantitative results of ELISA-1 and ELISA-2 are compared by plotting the results of 
ELISA-1 on the x-axis as U/mL and plotting the result of ELISA-2 on the Y-axis as S/Co. A polynomial trend-
line gives a R-squared value of 0.7534. Concordant positive results are presented as red dots, concordant 
negative results are presented as green dots, and concordant borderline results are presented as yellow dots. 
Fully discordant results are shown as black dots while partly discordant samples are shown as blue dots.  
b. A flowchart showing the result of ELISA-1, ELISA-2, ELISA-3 and strip-immunoassay. Samples with a 
borderline result (border n=5), a fully discordant result (n=18) or a partly discordant result (n=19) after ELISA-
1 and ELISA-2, where resolved by the use of ELISA-3 and strip-immunoassay. The results of ELISA-1 and 
ELISA-2 are presented as positive (pos), borderline (border) and negative (neg) anti-HEV IgG detection. The 
results of ELISA-3 and the strip-immunoassay are shown in red circles for positive results, green squares for 
negative results and white triangles for borderline results. ELISA-3 and strip-immunoassay confirmed or 
detected 31 additional positive samples giving a total number of 205 positive samples. 
 
Fig.3. Predicted probability of a positive anti-HEV IgG test using the data from 1800 participants of the 
population-based study Tromsø 7.  
a. The predicated probability of a positive anti-HEV IgG test with increasing age (n=1800). The 95% confidence 
interval is also shown.  
b. The predicated probability of a positive anti-HEV IgG test with increasing age for those with ≥4 years 
university or college education (n=498) compared with those with only primary school (n=453). The 95% 




        TABLE 1 Invited for Tromsø 7 study (T7) and participating in T7 and HEV study, respectively 


















































































































































































































































































Age 80 - 104 1946 761 
(39.1%) 
0 (0%) 1223 413 
(33.8%) 















Mean age  






















59.5  59.5  49.3  49.3  69.8  69.8  
Age  
40 - 49 







45.0 45.0 42.5 42.0 47.0 47.0 
Age  
50 - 59 







55.0 55.0 52.0 52.0 57.0 57.0 
Age  
60 - 69  







64.0 64.0 62.0 62.0 67.0 67.0 
Age  
70 - 79 







73.0 73.0 71.0 71.0 75.0 76.0 
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TABLE 3 Assays used for anti-HEV IgG detection  
Assay Producer Antigen for coating Serostatus interpretation 




Recombinant HEV ORF2 
(Genotype 1 and 3) 
Negative:    <20 U/mL      
Borderline:  20–24 U/mL  
Positive:      >24 U/mL 
HEV IgG ELISA         
(indirect sandwich-ELISA) 
Dia.Pro‡ Recombinant HEV antigens: 
Four synthetic peptides 
representing epitopes from 
ORF2 and ORF3 from the 
Burmese and Mexican HEV 
strains 
Negative:    S/Co < 0.9 
Borderline: S/Co 0.9–1.1 
Positive:     S/Co  >1.1 
Wantai HEV IgG ELISA 
(indirect sandwich-ELISA) 
Sanbio§ Recombinant HEV ORF2 C-
terminal part (Genotype 1) 
Negative:    C.O.<0.9  
Borderline: C.O.<0.9–1.1 
Positive:     C.O. >1.1 




Recombinant HEV antigens: 
ORF2 N-terminal part 
(Genotype 1 and 3), ORF2 
C-terminal part (Genotype 1 
and 3), ORF2 mid part 
(Genotype 1) and ORF3 
(Genotype 1 and 3) 
Negative:    ≤2              
Borderline:    3                  
Positive:      ≥4 

















































TABLE 4 Age-adjusted logistic regression analysis for each variable 
Variables OR 95% CI p-value 
Age (per year) 1.027 1.013-1.041 <0.001‡ 
Gender 
    Female 







  0.507 
Diabetes 
    Never or previously 







  0.591 
BMI† 1.028 1.962-1.029   0.761 
Smoking 
    Never 
    Previously 









  0.178‡ 
 
  0.104 
  0.174 
Eating red meat (beef, mutton, pork) 
    Never or rarely 







  0.796 
Travel outside Nordic countries last 12 






  0.091‡ 
Eating reindeer meat (times/year) 1.013 0.999-1.027   0.066‡ 
Eating moose meat (times/year) 1.003 0.989-1.017   0.645 
Education 
    Primary school 
    High school 
    <4 years in college/university    











  0.004‡ 
 
  0.084 
  0.169 
<0.001 
Total yearly income in the household  
    <450.000 NOK 
    451.000-750.000 NOK 









  0.019‡ 
 
  0.017 
  0.007 
Alcohol consumption 
    Never 
    Monthly or less  
    2-4 times a month 
    2-3 times a week 













  0.792 
  0.521 
  0.224 
 
  0.595 

















TABLE 5 Final results from backward stepwise regression 
Variables OR 95% CI p-value 
Age (per year) 1.036 1.021-1.051 <0.001* 
Education 
    Primary school 
    High school 
    <4 years in college/university    








































































































































































Figure 1a and b

























ELISA-1: Mikrogen HEV IgG
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Figure 2a and b
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